While I'm curious about the numbers and methodologies myself I am impressed by the restraint. I had previously predicted and marked the valuation with disdain, as it's common for small caps recapping to pay for a 3rd party valuation that will print just about anything and use it as a short term pump. Here they're keeping it pretty mum which may just be an angle, but has me thinking it really is a helpful starting point for negotiation. That's what we need. Interested parties talking about serious financing, not shenanigans ala buyins.net
(4)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links